Peptide-functionalized nanomaterials for controlled drug delivery and regenerative therapies in retinal diseases
- 4 November 2025
- journal article
- review article
- Published by SAGE Publications in Journal of Biomaterials Applications
- Vol. 40 (10) , 1235-1262
Abstract
Degenerative retinal diseases, such as diabetic retinopathy, age-related macular degeneration (AMD), and retinitis pigmentosa, cause irreversible vision loss by destroying vital retinal cells and represent major global health concerns. Traditional therapies have limited success in fully restoring vision due to the complex retinal structure and blood-retinal barriers (BRBs), though they may help alleviate symptoms or slow disease progression in some cases. Nanochemistry and peptide-based systems represent breakthrough approaches by leveraging nanoscale precision and biological specificity. This review examines the chemical design and synthesis of nanoparticles (NPs), nanoscaffolds, and peptide conjugates used in retinal neural regeneration. It also explores their biomedical applications, especially in targeted drug delivery, tissue engineering, and cellular repair. Biodegradable polymeric NPs, liposomes, and hybrid nanostructures are designed to cross barriers, release drugs in a controlled manner, and enhance biocompatibility. PEGylation improves stability and reduces immune responses in the ocular environment, while peptide functionalization enables specific cellular targeting and minimizes inflammatory reactions. Peptide-functionalized platforms, such as RGD-modified NPs and self-assembling hydrogels, provide receptor-mediated targeting and extracellular matrix (ECM) mimicry to support retinal regeneration for improved stem cell differentiation and neuroprotection. We discuss drug/gene delivery mechanisms, cellular interactions, and immune modulation, as well as neuroprotection, stem cell therapy, and diagnostic applications. Preclinical studies have demonstrated promising efficacy in animal models; however, concerns regarding scalability, long-term safety, and non-invasive delivery persist. Next-generation technologies, such as stimuli-responsive NPs, computationally designed peptides, and patient-specific delivery systems, are on the horizon to address unmet clinical needs. By marrying nanochemistry’s precision with peptides’ bioactivity, these technologies have the potential to transform retinal disease treatment, enabling the restoration of vision and an improvement in quality of life for millions of people worldwide.Keywords
This publication has 240 references indexed in Scilit:
- Lipid‐Based Nanoparticles in Cancer Therapy: Advances in Targeted Drug Delivery and Therapeutic Potential for Renal Cell CarcinomaAdvanced Science, 2025
- Harnessing Photo‐Energy Conversion in Nanomaterials for Precision TheranosticsAdvanced Materials, 2025
- Nanotherapy for Neural Retinal RegenerationAdvanced Science, 2025
- The Future of Nanomaterials Tackling the Challenge of Delivering Nucleic Acids to the RetinaAdvanced Functional Materials, 2024
- A Roadmap of Peptide‐Based Materials in Neural RegenerationAdvanced Healthcare Materials, 2024
- Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular DiseasesAdvanced Science, 2024
- Tailored Drug Delivery Platforms: Stimulus‐Responsive Core–Shell Structured NanocarriersAdvanced Healthcare Materials, 2023
- Protein and Peptide‐Based Nanotechnology for Enhancing Stability, Bioactivity, and Delivery of AnthocyaninsAdvanced Healthcare Materials, 2023
- Short Peptide Nanofiber Biomaterials Ameliorate Local Hemostatic Capacity of Surgical Materials and Intraoperative Hemostatic Applications in ClinicsAdvanced Materials, 2023
- Nanostructured Hydrogels for Three‐Dimensional Cell Culture Through Self‐Assembly of Fluorenylmethoxycarbonyl–DipeptidesAdvanced Materials, 2006